Bruce C. Trapnell, MD
Title
Assistant Director, Adult Cystic Fibrosis Center; Director, Viral Vector Core Laboratory
Appointment
Professor of Medicine and Pediatrics; Attending Physician; Co-Director, Cincinnati Cystic Fibrosis Therapeutics Development Center; Director, Rare Lung Diseases Clinical Research Foundation; Scientific Director, Alpha-1 Foundation, University of Cincinnati College of Medicine
Email
bruce.trapnell@cchmc.org
Phone
513-636-6361
Fax
513-636-3723
Bio
Dr. Trapnell received his MD from the University of Maryland in 1985, and completed a medical residency at The Ohio State University Hospitals and a fellowship in pulmonary medicine at the Clinical Center of the National Institutes of health, where he then served as Senior Attending Physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis, Pharma, serving as Vice President before joining Cincinnati Children’s Hospital Medical Center, where he is now Full Professor.
Dr. Trapnell has conducted lung disease research since his training and has been continuously funded by the NIH since 2001, shortly after his arrival in Cincinnati. He has published over 90 original articles and has trained more than 16 post-doctoral fellows. Dr. Trapnell’s research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.
He is Director of Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center, Assistant Director of the Adult Cystic Fibrosis Care Center, Director of the Rare Lung Diseases Clinical Research Consortium, Scientific Director of the Pulmonary Alveolar Proteinosis Foundation. Dr. Trapnell is past Scientific Director of the Alpha-1 Foundation, for which he organized and directed the grant program for eight years.
Credentials
MS: Genetics, The George Washington University, Washington, DC, 1981.
MD: University of Maryland School of Medicine, Baltimore, MD, 1984.
Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.
Fellowship: Pulmonary Medicine, Warren Grant Magnasun Clinical Center, National Institutes of Health, Bethesda, MD, 1989.
Certification: Diplomate in Internal Medicine, American Board of Internal Medicine, 1987; Diplomate, National Board of Medical Examiners, 1987; Diplomate in Pulmonary Medicine, American Board of Internal Medicine, 2000 .
Position History
Dr. Trapnell Joined Cincinnati Children's Hospital Medical Center in 1977. He currently holds appointments in the Divisions of Pulmonary Biology and Pulmonary Medicine in the Department of Pediatrics and the Division of Pulmonary, Sleep and Critical Care Medicine in the Department of Medicine at the University of Cincinnati.
Awards and Honors
- Francis R. Luther Endowed Chair, Departments of Pediatrics and Medicine, University of Cincinnati
- William J. Martin II, Distinguished Achievement Award, Public Advisory Council of the American Thoracic Society
Research
Dr. Trapnell's laboratory seeks to define mechanisms regulating innate immunity and inflammation in the lungs.
His major focus is alveolar macrophage function in health and disease and the regulation alveolar homeostasis and host defense by GM-CSF in health and disease. Clinical studies include novel diagnostic and therapeutic approaches for pulmonary alveolar proteinosis, cystic fibrosis, alpha-1 antitrypsin deficiency, lymphangioleiomyomatosis, hereditary interstitial lung diseases and other rare lung diseases.
A wide range of basic, clinical and translational research approaches are utilized to study mechanisms of disease pathogenesis and pulmonary innate immunity. Laboratory approaches include molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation. Clinical approaches include therapeutic drug trials at all phases as well as longitudinal studies.
Dr. Trapnell’s article, “Mechanism of Disease: Pulmonary Alveolar Proteinosis” published in the New England Journal of Medicine outlines the recent progress that has defined the pathogenesis of pulmonary alveolar proteinosis and the critical role of GM-CSF in the lung in health and disease. (LINK = http://content.nejm.org/cgi/content/full/349/26/2527).
Research Grants and Contracts
NIH U54 RR019498
Rare Lung Diseases Clinical Research Consortium
9/30/03-8/31/08
Role: Principal Investigator
CFF Specialized Clinical Center
Cystic Fibrosis Therapeutics Development Network (TDN) Center
7/1/98-10/31/09
Role: Principal Investigator
NIH R01 HL085453-01A1
Role of Anti-GM-CSF Antibodies in Myeloid Cell Function & Innate Immunity
04/01/07-03/31/12
Role: Principal Investigator
NIH R01 HL086598-01A1
Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
04/01/07-03/31/11
Role: Co-Investigator
Publications, Most Recent
Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF, Oh-eda M, Ishige I, Eishi Y, Kitamura T, Yamada Y, Hanaoka K, and N Keicho. High Affinity Autoantibodies Specifically Eliminate Granulocyte-Macrophage Colony-Stimulating Factor Activity In The Lungs Of Patients With Idiopathic Pulmonary Alveolar Proteinosis. (In Press).
Katakura S, Jennings K, Watanabe S, Gao G-P, Wilson JM, Burstein H, Trapnell BC, and Hirsch R. Recombinant Adeno-associated Virus preferentially transduces human, compared to mouse, synovium: implications for therapy of arthritis. (In Press).
Cheng Y-H, Aronow BJ, Hossain S, Trapnell BC, Kong S and Handwerger S. Critical role for transcription factor AP-2 in human trophoblast differentiation. (In press).
Jennings K, Miyamae T, Katakura S, Trapnell BC, Wilson JM, Gao G, Sowders D, and R Hirsch. Proteasome Inhibition Enhances AAV-Mediated Transduction fo Human Synoviocytes In Vitro and In Vivo.
Shibata Y, Berclaz P-Y, Chroneos ZC, Whitsett JA and Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15: 557-567; 2001.
Trapnell BC, Whitsett JA, and K Nakata. Mechanism of Disease: Pulmonary Alveolar Proteinosis. New Engl. J. Med. 349: 2527-2539; 2003.
Gonzalez-Juarrero M, Hattle JM, Izzo A, Junquiera-Kipnis AP, Shim TS, Trapnell BC, Cooper AM, Orme IM. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol. 77: 914-922; 2005.
Berclaz PY, Carey B, Filippi MD, Wernke-Dollries K, Geraci N, Cush S, Richardson T, Kitzmiller J, O’Connor M, Hermoyian C, Korfhagen T, Whitsett J, Trapnell BC. GM-CSF Regulates a PU.1-Dependent Transcriptional Program Determining the Pulmonary Response to LPS. Am J Respir Cell Mol Biol. 36: 114-121; 2007.
Uchida K, Beck D, Yamamoto T, Berclaz PY, Shuichi A, Staudt M, Carey B, Filippi MD, Wert S, Denson L, Puchalski J, Hauck D, Trapnell BC. GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis. New Engl. J. Med. 356: 567-579; 2007.
Carey B, Staudt MK, Bonaminio D, van der Loo JM, and Trapnell BC. PU.1 Redirects Adenovirus to Lysosomes in Alveolar Macrophages, Uncoupling Internalization from Infection.
J Immunol. 178: 2240-2447; 2007.
Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, Hoshino Y, Kagamu H, Yoshizawa H, Keicho N, Goto H, Nakata K. Anti-cytokine autoantibodies are ubiquitous in health individuals. FEBS Let. 581: 2017-2021; 2007.
Deutsch G, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA, Brody AS, Nogee LM, Trapnell BC, Langston. Diffuse parenchymal lung disease in young children: application of a novel clinical-pathologic classification scheme.Am J Resp Crit Care Med. 176.: 1120-1128; 2007.
Perlmutter D, Brodsky JL, Balistreri WF, Trapnell BC. Molecular Pathogenesis of Alpha-1-Antitrypsin Deficiency-Associated Liver Disease: A Meeting Review. Hepatology. 45: 1313-1323; 2007.
Bendtzen K, Svenson M, Hansen MB, Busch T, Bercker S, Kaisers U, Uchida K, Beck DC, Trapnell BC. GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis. N Engl J Med 356:2001-2; 2007.
Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, and Nakata K for the Japanese Center of the Rare Lung Diseases Consortium. Characteristics of a Large Cohort of Autoimmune Pulmonary Alveolar Proteinosis Patients In Japan.
Am J Resp Crit Care Med. 177: 752-62; 2008.
Spight D, Trapnell BC, Shao B, Berclaz P, Shanley TP. GM-CSF-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice. Shock. 30:434-442; 2008.
Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, Poremba C, Flasshove M, Opalka B, Trapnell BC, Dirksen U, and Moritz T. Gene Therapy of beta c-deficient pulmonary alveolar proteinosis (beta c-PAP): Studies in a murine in vivo model.
Mol Therapy. 16: 757-764; 2008.
Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, Grabowski G, Carey BC, Stevens C, van der Loo JC, Trapnell BC. Familial Pulmonary Alveolar Proteinosis Caused by Mutations in CSF2RA.J Exp Med. 205: 2703-2710; 2008.
Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman E, Everett SE, Stoller JK. α1 –Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes*. Chest. 134: 831-834; 2008.
Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch D, Stevens CA, Beck DC, Denson LA, Carey BC, Keicho N, Krischer JP, Yamada Y, Trapnell BC. Granulocyte/Macrophage Colony Stimulating Factor Autoantibodies and Myeloid Cell Immune Functions In Healthy Individuals.Blood. 113: 2547-2556; 2009.
Robinson TE, Trapnell BC, Goris M, Quittell L, Cornfield D. Quantitative Analysis Of Longitudinal Response to Aerosolized GM-CSF In 2 Adolescents With Autoimmune Pulmonary Alveolar Proteinosis.Chest. 135:842-48; 2009.
Luisetti M, Rodi G, Perotti C, Campo I, Mariani F, Pozzi E, Trapnell BC. Plasmapheresis for Treatment of Pulmonary Alveolar Proteinosis. Eur.Resp.J. Eur.Resp.J. 33:1-3; 2009.
Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, Bonkowski E, Kim M-Q, Tomer G, Dubinsky M, Plevy S, Kugathsan S, Trapnell BC, Denson LA. Granulocyte-Macrophage Colony Stimulating Factor Auto-antibodies in Murine Ileitis and Progressive Ileal Crohn’s Disease. Gastroenterology. (In press)
Presentations, Most Recent
Invited Speaker, The Rare Lung Diseases Consortium: Disorders, Defects and Development of Novel Therapies, The First International Congress On Rare Diseases and Orphan Drugs, Stockholm, Sweden; 2005
Conference Organizer and Co-Chair, Second Annual Rare Lung Diseases Conference, Cincinnati, Ohio; 2005.
Chairman and Co-organizer, Third Annual International Pulmonary Alveolar Proteinosis Scientific Conference, Osaka, Japan. 2005
Chairman, Session on Improving Diagnosis & Earlier Treatment, European Platform for Patients’ Organizations, Science and Industry, London, England, 2005
Conference Organizer and Co-Chair, Third Annual Rare Lung Diseases Conference, Cincinnati, Ohio, 2006.
Conference Organizer and Co-Chari, Fourth Annual Pulmonary Alveolar Proteinosis Scientific Conference, Cincinnati, Ohio, 2006.
Chairman and Co-organizer, Fifth Annual International Pulmonary Alveolar Proteinosis Scientific Conference, Osaka, Japan, 2007.
Chairman, RLDC – JRS Joint Symposium Rare Lung Diseases: Pathogenesis and Treatment, Annual Meeting of the Japanese Respiratory Society, Tokyo, Japan. 2007.
Invited Keynote Speaker, Autoimmune Pulmonary Alveolar Proteinosis: Recent Progress on Pathogenesis and Therapy, Annual Meeting of the Japanese Respiratory Society, Tokyo, Japan, 2007.
Professional Organization Memberships
Special Interests
Pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; other rare lung disorders.
Editing
Dr. Trapnell serves as an ad hoc reviewer for the following journals:
Other Programs, Services and Clinics of Work
- Co-Director, Cystic Fibrosis Therapeutics Development Center, Children’s Hospital Medical Center, Cincinnati, OH
- Assistant Director, Adult Cystic Fibrosis Center, U. of Cincinnati Medical Center, Cincinnati, OH
- Scientific Director, Pulmonary Alveolar Proteinosis Foundation, Denver, CO
- Member, Medical and Scientific Advisory Council, Alpha 1 Foundation, Miami, FL
- Member, Data Safety Monitoring Committee, Cystic Fibrosis Foundation, Bethesda, MD
- Member, Research and Training Grant Review Committee, Alpha 1 Foundation, Miami, FL
- Editorial Board, Journal of Clinical and Translational Science
- Editorial Board, Alpha-1 to One
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical
Center:
